{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:23:07Z","timestamp":1790742187981,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012820","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000}}],"reference-count":158,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012820.pub2","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T08:28:47Z","timestamp":1631867327000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cannabinoids for the treatment of dementia"],"prefix":"10.1002","volume":"2021","author":[{"given":"Dina","family":"Bosnjak Kuharic","sequence":"additional","affiliation":[{"name":"University Psychiatric Hospital Vrap\u010de; Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domagoj","family":"Markovic","sequence":"additional","affiliation":[{"name":"Clinic for Heart and Cardiovascular Diseases; University of Split Hospital Center; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonci","family":"Brkovic","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine; University of Split Hospital Center; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milka","family":"Jeric Kegalj","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology; General Hospital Zadar; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zana","family":"Rubic","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology; University of Split Hospital Center; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vuica Vukasovic","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine; University of Split Hospital Center; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jeroncic","sequence":"additional","affiliation":[{"name":"Department of Research in Biomedicine and Health; University of Split School of Medicine; Split Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Puljak","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Medicine and Health Care; Catholic University of Croatia; Zagreb Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,17]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD012820.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0002|cit2","unstructured":"Safety and efficacy of nabilone in Alzheimer's disease: a pilot study https:\/\/clinicaltrials.gov\/show\/NCT02351882"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Ruthirakuhan M Herrmann N Abraham EH Sherman C Verhoeff NPLG Kiss A A randomized, placebo-controlled, cross-over trial investigating nabilone as a treatment for agitation in patients with moderate-to-severe Alzheimer's disease: blinded, interim safety results Alzheimer's & Dementia: Journal of the Alzheimer's Association 2017 1254 10.1016\/j.jalz.2017.06.1867","DOI":"10.1016\/j.jalz.2017.06.1867"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/JAD-190202","article-title":"24S-Hydroxycholesterol is associated with agitation severity in patients with moderate-to-severe Alzheimer's disease: analyses from a clinical trial with nabilone","volume":"71","author":"Ruthirakuhan","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/0891988719874118","article-title":"Agitation, oxidative stress, and cytokines in Alzheimer disease: biomarker analyses from a clinical trial with nabilone for agitation","volume":"33","author":"Ruthirakuhan","year":"2020","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0006|cit6","unstructured":"Ruthirakuhan M Herrmann N Andreazza AC Verhoeff NPLG Gallagher D Black SE Investigating biomarkers of agitation in moderate-to-severe Alzheimer's disease patients enrolled in a randomized controlled trial with nabilone Alzheimer's and Dementia 2017 P1169 10.1016\/j.jalz.2018.06.1609"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0007|cit7","unstructured":"Ruthirakuhan M Herrmann N Gallagher D Verhoeff NPLG Black SE Lanctot KL Cerebrocholesterol, a marker of agitation severity in patients with moderate-to-severe Alzheimer's disease Alzheimer's and Dementia 2018 P1552 3 10.1016\/j.jalz.2018.07.098"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0008|cit8","unstructured":"Ruthirakuhan M Herrmann N Liu C Abraham E Kiss A Andreazza AC Designing a randomized placebo-controlled crossover trial investigating nabilone as a treatment for agitation in patients with moderate to severe Alzheimer's disease Alzheimer's & Dementia 2016 P1014 15 10.1016\/j.jalz.2016.06.2092"},{"issue":"100385","key":"10.1002\/14651858.CD012820.pub2-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2019.100385","article-title":"Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: study protocol for a cross-over randomized controlled trial","volume":"15","author":"Ruthirakuhan","year":"2019","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"14","key":"10.1002\/14651858.CD012820.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s00213-015-3889-y","article-title":"Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia","volume":"232","author":"Ahmed","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0011|cit11","unstructured":"Two phase, repeated crossover study with dose escalation on delta(9)-tetrahydrocannabinol (delta-THC) in behavioral disturbances in dementia https:\/\/clinicaltrials.gov\/show\/NCT01302340"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial","volume":"12","author":"den Elsen","year":"2015","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/0269881116665357","article-title":"Effects of tetrahydrocannabinol on balance and gait in patients with dementia: a randomised controlled crossover trial","volume":"31","author":"den Elsen","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0014|cit14","unstructured":"Efficacy and safety of delta-9-tetrahydrocannabinol (\u22069-THC) in behavioural disturbances and pain in dementia https:\/\/clinicaltrials.gov\/show\/NCT01608217"},{"issue":"23","key":"10.1002\/14651858.CD012820.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"den Elsen","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"van den Elsen GAH Ahmed AIA Verkes RJ Kramers K Feuth T Olde Rikkert MGM Efficacy and safety of delta-9-tetrahydrocannabinol in behavioral disturbances in dementia: a randomized controlled trial Alzheimer's & Dementia 2015 P469 70 10.1016\/j.jalz.2015.06.498","DOI":"10.1016\/j.jalz.2015.06.498"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Volicer L Stelly M Morris J McLaughlin J Volicer BJ Rogers EN Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease Neurobiology of Aging Osaka, Japan 1996 S73 4 10.1016\/S0197-4580(96)80294-6","DOI":"10.1016\/S0197-4580(96)80294-6"},{"issue":"9","key":"10.1002\/14651858.CD012820.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease","volume":"12","author":"Volicer","year":"1997","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0019|cit19","first-page":"1338","article-title":"Dronabinol may help behavior problems in Alzheimer's disease","volume":"55","author":"Volicer","year":"1997","journal-title":"American Family Physician"},{"issue":"3-4","key":"10.1002\/14651858.CD012820.pub2-BIB0020|cit20","first-page":"142","article-title":"Synthetic cannabinoids in dementia with agitation: case studies and literature review","volume":"10","author":"Amanullah","year":"2013","journal-title":"Clinical Neuropsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/WNF.0b013e3181633497","article-title":"Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study","volume":"32","author":"Aragona","year":"2009","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JAD-200426","article-title":"Combined with luteoline on frontal lobe functions, high frequency oscillations, and GABAergic transmission in patients with frontotemporal dementia","volume":"76","author":"Assogna","year":"2020","journal-title":"Journal of Alzheimer's Disease"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD012820.pub2-BIB0023|cit23","first-page":"P755","article-title":"Advancing research and treatment of frontotemporal lobar degeneration (ARTFL): preparing for clinical trials for FTLD in North America","volume":"11","author":"Boxer","year":"2015","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000498924","article-title":"Prescription of a THC\/CBD-based medication to patients with dementia: a pilot study in Geneva","volume":"2","author":"Broers","year":"2019","journal-title":"Medical Cannabis and Cannabinoids"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012820.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"A62","DOI":"10.1136\/jnnp-2012-303524.193","article-title":"A double blind, cross over, placebo-controlled, phase II trial of Sativex in Huntington's disease","volume":"83","author":"Caldentey","year":"2012","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD012820.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012820.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/S0924-977X(13)70868-X","article-title":"Cannabidiol add-on usual treatment improves the outcome of patients with Parkinson's disease","volume":"23","author":"Chagas","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"15","key":"10.1002\/14651858.CD012820.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0031|cit31","unstructured":"Euctr ES Study to evaluate the safety, tolerability and anti-inflammatory effect of three oromucosal doses of Sativex\u00ae in patients with early Alzheimer dementia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-004169-18-ES 2016"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1212\/01.wnl.0000304046.23960.25","article-title":"Multiple sclerosis and cannabis: a cognitive and psychiatric study","volume":"71","author":"Ghaffar","year":"2008","journal-title":"Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD012820.pub2-BIB0033|cit33","first-page":"A109","article-title":"Dronabinol for the treatment of behavioral and mood disturbances in dementia","volume":"17","author":"Kahraman","year":"2009","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/ijms18010026","article-title":"Cannabidiol modulates the expression of alzheimer's disease-related genes in mesenchymal stem cells","volume":"18","author":"Libro","year":"2017","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00391-007-0420-z","article-title":"Actigraphy in agitated patients with dementia. Monitoring treatment outcomes","volume":"40","author":"Mahlberg","year":"2007","journal-title":"Zeitschrift f\u00fcr Gerontologie und Geriatrie"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0036|cit36","unstructured":"Dronabinol interactions in humans https:\/\/clinicaltrials.gov\/show\/NCT00842985"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0037|cit37","unstructured":"A multicentre, double-blind, randomised, parallel group, placebo-controlled study of the effect of long-term treatment with Sativex on cognitive function and mood of Patients with spasticity due to multiple sclerosis https:\/\/clinicaltrials.gov\/show\/NCT01964547"},{"issue":"49","key":"10.1002\/14651858.CD012820.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"38543","DOI":"10.1074\/jbc.M110.162040","article-title":"Endocannabinoids prevent beta-amyloid-mediated lysosomal destabilization in cultured neurons","volume":"285","author":"Noonan","year":"2010","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/gps.1828","article-title":"The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation","volume":"23","author":"Passmore","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1476-5381.2010.00831.x","article-title":"The endocannabinoid system as a target for the treatment of neurodegenerative disease","volume":"3","author":"Scotter","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-150915","article-title":"Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study","volume":"51","author":"Shelef","year":"2016","journal-title":"Journal of\u00a0Alzheimer's Disease"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/S0924-977X(14)70333-5","article-title":"Opposite effects of THC and CBD on auditory mismatch negativity: a randomised controlled trial of acute cannabinoid administration","volume":"Suppl 2","author":"Solowij","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0030-1255030","article-title":"Delta-9-tetrahydrocannabinol disruption of time perception and of self-timed actions","volume":"43","author":"Stone","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"524\u20138","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JCP.0b013e31820e861c","article-title":"Randomized, controlled crossover trial of dronabinol, 2.5 mg, for agitation in 2 patients with dementia","volume":"31","author":"Walther","year":"2011","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/JCP.0000000000000805","article-title":"Dextrometorphan-paroxetine, but not dronabinol, effective for treatment-resistant aggression and agitation in an elderly patient with Lewy body dementia","volume":"37","author":"Wilhelm","year":"2017","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"American Journal of\u00a0Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"10.4088\/PCC.14l","DOI":"10.4088\/PCC.14l01695","article-title":"Nabilone for the treatment of dementia associated sexual disinhibition","volume":"17","author":"Zajac","year":"2015","journal-title":"Primary Care Companion\u00a0for\u00a0CNS\u00a0Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012820.pub2-BIB0049|cit49","first-page":"S86","article-title":"A phase II, randomized, double-blind, placebocontrolled trial to investigate the efficacy and safety of Avidekel oil for the treatment of patients with agitation related to dementia","volume":"68","author":"Hermush","year":"2020","journal-title":"Journal of the American Geriatrics Society"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012820.pub2-BIB0050|cit50","first-page":"S164","article-title":"A phase II, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of avidekel oil for the treatment of patients with agitation related to dementia","volume":"11","author":"Hermush","year":"2020","journal-title":"European Geriatric Medicine"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0051|cit51","unstructured":"The effect of cannabis on dementia related agitation and aggression https:\/\/clinicaltrials.gov\/show\/nct03328676 2017"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0052|cit52","unstructured":"Medicinal cannabis and dementia: effects on behavioural symptoms among older residential care recipients https:\/\/anzctr.org.au\/ACTRN12619000474156.aspx 2019"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0053|cit53","unstructured":"Medicinal cannabis use among dementia patients http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12619000474156 2019"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13063-020-4085-x","article-title":"Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial","volume":"21","author":"Vickery","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0055|cit55","unstructured":"Euctr NL Two phase, repeated crossover study with dose escalation on delta(9)-tetrahydrocannabinol (delta-THC) in behavioral disturbances in dementia. Delta-THC in behavioral disturbances in dementia http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2010-024577-39-NL 2019"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0056|cit56","unstructured":"Cannabidiol for behavioural symptoms in Alzheimer's disease https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-002106-52\/GB 2019"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0057|cit57","unstructured":"A randomised feasibility trial investigating Sativex\u00ae for the treatment of the agitation and aggression (A\/A) in Alzheimer\u2019s dementia https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001056-17\/GB 2020"},{"issue":"7","key":"10.1002\/14651858.CD012820.pub2-BIB0058|cit58","first-page":"940","article-title":"Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD) (THC-AD)","volume":"13","author":"Forester","year":"2017","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0059|cit59","unstructured":"Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD) (THC-AD) https:\/\/clinicaltrials.gov\/show\/NCT02792257"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.jagp.2021.01.111","article-title":"Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (THC-AD)","volume":"29","author":"Outen","year":"2021","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jagp.2020.01.150","article-title":"Trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD) (THC-AD)","volume":"28","author":"Rosenberg","year":"2020","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.jagp.2020.01.150","article-title":"Trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD) (THC-AD)","volume":"28","author":"Rosenberg","year":"2020","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0063|cit63","unstructured":"Effects of THC-free CBD oil on agitation in patients with Alzheimer's disease https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04436081"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0064|cit64","unstructured":"Nabilone for agitation blinded intervention trial (NAB-IT) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04516057 2020"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0065|cit65","unstructured":"Alzheimer's Disease International (ADI) World Alzheimer Report 2016 www.alz.co.uk\/research\/WorldAlzheimerReport2016.pdf"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.euroneuro.2013.10.002","article-title":"In vivo type 1 cannabinoid receptor availability in Alzheimer's disease","volume":"24","author":"Ahmad","year":"2014","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.117","article-title":"Cannabinoids in late-onset Alzheimer's disease","volume":"97","author":"Ahmed","year":"2015","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0068|cit68","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"2013"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JAD-2012-111862","article-title":"CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AbetaPP\/PS1 mice","volume":"30","author":"Aso","year":"2012","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JAD-130137","article-title":"CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AbetaPP\/PS1 mice","volume":"35","author":"Aso","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fphar.2014.00037","article-title":"Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic","volume":"5","author":"Aso","year":"2014","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0706743719892717","article-title":"Cannabinoids for the neuropsychiatric symptoms of dementia: a systematic review and meta-analysis","volume":"65","author":"Bahji","year":"2020","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","article-title":"The therapeutic potential of cannabis","volume":"2","author":"Baker","year":"2003","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"Atypical antipsychotics for aggression and psychosis in Alzheimer\u2019s disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.msard.2016.09.008","article-title":"Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis","volume":"10","author":"Banwell","year":"2016","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"5","key":"10.1002\/14651858.CD012820.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gps.490","article-title":"The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients","volume":"17","author":"Beeri","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000051230","article-title":"The Gottfries-Brane-Steen scale: validity, reliability and application in anti-dementia drug trials","volume":"12","author":"Brane","year":"2001","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1196\/annals.1432.037","article-title":"Ultrastructural localization of neuronal brain CB2 cannabinoid receptors","volume":"1139","author":"Brusco","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1017\/S1462399409000957","article-title":"Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation","volume":"11","author":"Cabral","year":"2009","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bjp.0707446","article-title":"Alzheimer\u2019s disease; taking the edge off with cannabinoids?","volume":"152","author":"Campbell","year":"2007","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/07317115.2020.1742832","article-title":"Effectiveness of cannabinoids for treatment of dementia: a systematic review of randomized controlled trials","volume":"44","author":"Charernboon","year":"2021","journal-title":"Clinical\u00a0Gerontologist"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.neuroscience.2011.01.024","article-title":"Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults","volume":"178","author":"Chen","year":"2011","journal-title":"Neuroscience"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"Journal of Gerontology"},{"issue":"12","key":"10.1002\/14651858.CD012820.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"7109","key":"10.1002\/14651858.CD012820.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of CB2 suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"Journal of Neuroinflammation"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0087|cit87","unstructured":"EndNote Thomson Reuters 2011"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer\u2019s disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Molecular Pharmaceutics"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0089|cit89","unstructured":"Centre for Drug Evaluation and Research FDA public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\"Mini-mental state\". a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012820.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/02791072.2017.1292434","article-title":"Medical cannabis in Serbia: the survey of knowledge and attitudes in an urban adult population","volume":"49","author":"Gazibara","year":"2017","journal-title":"Journal of Psychoactive Drugs"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1755-5949.2010.00195.x","article-title":"The multiplicity of action of cannabinoids: implications for treating neurodegeneration","volume":"17","author":"Gowran","year":"2011","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0094|cit94","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime, Inc.)"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/13543784.11.10.1365","article-title":"The therapeutic potential of the cannabinoids in neuroprotection","volume":"11","author":"Grundy","year":"2002","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuro.2011.12.015","article-title":"Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro","volume":"33","author":"Harvey","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0098|cit98","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD012820.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"204209861984699","DOI":"10.1177\/2042098619846993","article-title":"Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review","volume":"15","author":"Hillen","year":"2019","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"8","key":"10.1002\/14651858.CD012820.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/gps.2607","article-title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","volume":"26","author":"Howard","year":"2011","journal-title":"International Journal of\u00a0Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpainsymman.2013.05.002","article-title":"Cannabinoids","volume":"46","author":"Howard","year":"2013","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"161\u2013202","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology XXVII.Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacological Reviews"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0103|cit103","volume-title":"The science of marijuana","author":"Iversen","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD012820.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-013-9984-x","article-title":"Cannabinoid effects on beta amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro","volume":"34","author":"Janefjord","year":"2014","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jclinepi.2016.01.002","article-title":"Extracting data from figures with software was faster, with higher interrater reliability than manual extraction","volume":"74","author":"Jelicic Kadic","year":"2016","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1574884711666160418105339","article-title":"Endocannabinoid system: a multi-facet therapeutic target","volume":"11","author":"Kaur","year":"2016","journal-title":"Current Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007204.pub2","article-title":"Cannabinoids for the treatment of dementia","author":"Krishnan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0108|cit108","first-page":"e1","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"10","author":"Liberati","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"301","DOI":"10.9758\/cpn.2017.15.4.301","article-title":"A systematic review of\u00a0the effectiveness of medical cannabis for psychiatric,\u00a0movement and neurodegenerative disorders","volume":"15","author":"See","year":"2017","journal-title":"Clinical\u00a0Psychopharmacology and Neuroscience"},{"issue":"8","key":"10.1002\/14651858.CD012820.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40263-015-0270-y","article-title":"Cannabinoids for the treatment of agitation and aggression in Alzheimer's disease","volume":"29","author":"Liu","year":"2015","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1002\/14651858.CD012820.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.2174\/1567205013666160502122933","article-title":"Pharmacological management of agitation and aggression in Alzheimer's disease: a review of current and novel treatments","volume":"13","author":"Liu","year":"2016","journal-title":"Current Alzheimer Research"},{"issue":"7","key":"10.1002\/14651858.CD012820.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD012820.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.tibs.2010.05.008","article-title":"Intracellular trafficking of anandamide: new concepts for signaling","volume":"35","author":"Maccarrone","year":"2010","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-2094-9-8","article-title":"Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice","volume":"9","author":"Martin-Moreno","year":"2012","journal-title":"Journal of Neuroinflammation"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer's & Dementia"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0118|cit118","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) New advice issued on risperidone and olanzapine"},{"issue":"Pt 4","key":"10.1002\/14651858.CD012820.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/brain\/awr046","article-title":"Molecular reorganization of endocannabinoid signalling in Alzheimer's disease","volume":"134","author":"Mulder","year":"2011","journal-title":"Brain"},{"issue":"8","key":"10.1002\/14651858.CD012820.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","article-title":"Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores","volume":"65","author":"O'Bryant","year":"2008","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"231\u201346","DOI":"10.1159\/000100778","article-title":"Neuropsychological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain","volume":"54","author":"Onaivi","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1196\/annals.1432.036","article-title":"Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression","volume":"1139","author":"Onaivi","year":"2008","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"17","key":"10.1002\/14651858.CD012820.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1517\/14656566.2015.1092520","article-title":"Progresses in treating agitation: a major clinical challenge in Alzheimer's disease","volume":"16","author":"Panza","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0124|cit124","unstructured":"Peprah K McCormack S Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2019"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1208\/aapsj070364","article-title":"The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids","volume":"7","author":"Pertwee","year":"2005","journal-title":"AAPS Journal"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2)","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacological Reviews"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0127|cit127","first-page":"333\u20135","article-title":"The impact of dementia on the family","volume":"248","author":"Rabins","year":"1982","journal-title":"Journal of the American Medical Society"},{"issue":"8","key":"10.1002\/14651858.CD012820.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2046-4053-4-6","article-title":"Better duplicate detection for systematic reviewers: evaluation of Systematic Review Assistant-Deduplication Module","volume":"4","author":"Rathbone","year":"2015","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0130|cit130","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia - diagnostic-criteria for research studies - report of the NINDS-AIREN International Workshop","volume":"43","author":"Roman","year":"1993","journal-title":"Neurology"},{"issue":"11","key":"10.1002\/14651858.CD012820.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"18r12617","DOI":"10.4088\/JCP.18r12617","article-title":"Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: a meta-analysis","volume":"80","author":"Ruthirakuhan","year":"2019","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's disease cooperative study - Clinical Global Impression of Change","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1934\u201343","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death withatypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"191\u2013210","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0137|cit137","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11. Presenting results and \u2018Summary of findings' tables. In: Higgins JT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) Cochrane. Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/YCO.0000000000000399","article-title":"Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia","volume":"31","author":"Sherman","year":"2018","journal-title":"Current Opinion in Psychiatry"},{"issue":"340","key":"10.1002\/14651858.CD012820.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"23","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012820.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","article-title":"CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients","volume":"34","author":"Solas","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/1753-6405.12700","article-title":"A simulation of dementia epidemiology and resource use in Australia","volume":"42","author":"Standfield","year":"2018","journal-title":"Australian and New Zealand Journal of Public Health"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0143|cit143","first-page":"1049\u201351","article-title":"Psychiatric symptoms and nursing home placement of patients with Alzheimer\u2019s disease","volume":"147","author":"Steele","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/3-540-26573-2_11","article-title":"Effects of cannabinoids on neurotransmission","volume":"168","author":"Szabo","year":"2005","journal-title":"Handbook of Experimental Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD012820.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/09540261.2013.849663","article-title":"The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset","volume":"25","author":"Tschanz","year":"2013","journal-title":"International Review of Psychiatry"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0146|cit146","unstructured":"United Nations Office on Drugs and Crime (UNODC) World Drug Report 2017. Market analysis of plant-based drugs. Opiates, cocaine, cannabis https:\/\/www.unodc.org\/wdr2017\/field\/Booklet_3_Plantbased_drugs.pdf"},{"issue":"23","key":"10.1002\/14651858.CD012820.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"den Elsen","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"329\u201332","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"issue":"14","key":"10.1002\/14651858.CD012820.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1523\/JNEUROSCI.0786-09.2009","article-title":"Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K\/Akt pathway","volume":"29","author":"Viscomi","year":"2009","journal-title":"Journal of Neuroscience"},{"issue":"10","key":"10.1002\/14651858.CD012820.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jclinepi.2014.11.016","article-title":"Survey of Cochrane protocols found methods for data extraction from figures not mentioned or unclear","volume":"68","author":"Vucic","year":"2015","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/ph3082689","article-title":"Cannabinoids and dementia: a review of clinical and preclinical data","volume":"17","author":"Walther","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"issue":"13","key":"10.1002\/14651858.CD012820.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1503\/cmaj.071178","article-title":"Adverse effects of medical cannabinoids: a systematic review","volume":"178","author":"Wang","year":"2008","journal-title":"Canadian Medical Association Journal"},{"issue":"8","key":"10.1002\/14651858.CD012820.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11910-017-0766-6","article-title":"The use of cannabinoids in treating dementia","volume":"17","author":"Weier","year":"2017","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"24","key":"10.1002\/14651858.CD012820.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0155|cit155","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th revision","author":"World Health Organization (WHO)","year":"2010"},{"key":"10.1002\/14651858.CD012820.pub2-BIB0156|cit156","unstructured":"World Health Organization (WHO) Alzheimer Disease and Other Dementias www.who.int\/medicines\/areas\/priority_medicines\/BP6_11Alzheimer.pdf"},{"issue":"3","key":"10.1002\/14651858.CD012820.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiology of Aging"},{"issue":"2","key":"10.1002\/14651858.CD012820.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/gps.2499","article-title":"Assessing neuropsychiatric symptoms in nursing home patients with dementia: Reliability and Reliable Change Index of the Neuropsychiatric Inventory and the Cohen-Mansfield Agitation Inventory","volume":"26","author":"Zuidema","year":"2011","journal-title":"International Journal of\u00a0Geriatric Psychiatry"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T13:48:04Z","timestamp":1723470484000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012820.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":158,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012820.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]}}}